Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomizationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN within 30 days of day 1 of studyXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULNXx_NEWLINE_xXWithin 6 weeks prior to randomization: Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab\r\n* Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be =< 1.5 x ULNXx_NEWLINE_xXWithin 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 3 x IULNXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Alanine aminotransferase (ALT, SGPT) =< 2.5 x ULNXx_NEWLINE_xXSerum alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x IULN within 28 days prior to registrationXx_NEWLINE_xXAlanine (ALT) or aspartate (AST) aminotransferase > 1.5 x ULNXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)Xx_NEWLINE_xXWithin less than or equal to 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (=< 5 x IULN secondary to lymphoma) within 28 days prior to registrationXx_NEWLINE_xXObtained within 28 days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 4 weeks of randomizationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXObtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x institutional ULN, within 21 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registrationXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 1 registrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 3 registrationXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 upper limits of normal (ULN)\r\n* Unless due to hepatic metastases in which case levels =< 5 x ULN are allowedXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3.0 X ULN, within 14 days of registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3X the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times the institutional ULN (unless elevated secondary to lymphomatous involvement of the liver, in which case the AST/ALT must be =< 5 times the institutional ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULNXx_NEWLINE_xXAlanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN (may not have abnormalities in both bilirubin and transaminases)Xx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for patients with liver metastasesXx_NEWLINE_xXAlanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvementXx_NEWLINE_xXSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis) (=< 28 days prior to registration)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN obtained within 14 days prior to registrationXx_NEWLINE_xXAlanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (or =< 5.0 x ULN if liver metastases are present)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN) must be met within 28 days of C1D1Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN\r\n* Note that physician attestation of patient having no known history of liver disease can take the place of bilirubin and AST/ALT labsXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN.Xx_NEWLINE_xXIn case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN; if liver metastases are present, then ? 5 x ULN is allowed.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) at most 3 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and/or ALT ? 2.5 × ULNXx_NEWLINE_xXSerum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 2.5 x ULN in the absence of liver metastases and =< 5 x ULN in case of liver metastasesXx_NEWLINE_xXSerum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) < 2.5 × ULN; serum bilirubin < 1.5 × ULNXx_NEWLINE_xXAdequate liver function (total bilirubin ? 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; for patients with hepatic metastases, ALT and AST =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x ULN; if liver metastases, ALT/AST =< 5.0 x ULNXx_NEWLINE_xXWithin 30 days prior to enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAlanine aminotransferase (ALT) < 5 times ULNXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULNXx_NEWLINE_xXAlanine aminotransferase or aspartate aminotransferase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasisXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT [SGPT]) ?2.5 × the ULN;Xx_NEWLINE_xXSerum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT)/aspartate aminotransferase (AST), should be less than or equal to 1.5 x ULN (CTCAE v4.0, grade 1); for patients with liver metastases, ALT/AST should be less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN within 7 days before the first dose of cabozantinibXx_NEWLINE_xXAspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN; AST and ALT ? 5 × ULN for patients with liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST must be =< 5 x ULN.Xx_NEWLINE_xXWithin 10 (except as noted) days of planned treatment initiation: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN OR =< 5 x ULN for patients with known liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastasesXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase, alanine aminotransferase, alkaline phosphatase =< 2.5 x ULN, or =< 5 x ULN in subjects with liver metastases within 28 days of treatment initiation and must be independent of hematopoietic growth factor supportXx_NEWLINE_xXObtained within 14 days prior to C1D1: Alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) should be below 3.0 × ULN. If the participant has liver metastases, ALT and AST should be below 5.0 × ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 × ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 10 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × institutional ULN.Xx_NEWLINE_xXAspartate and alanine aminotransferase (AST and ALT) =< 2.5 x ULN; =< 5.0 x ULN if there is liver involvement secondary to tumorXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULNXx_NEWLINE_xXObtained =< 2 weeks prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN (=< 5 x ULN if liver metastasis)Xx_NEWLINE_xXObtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN or < 5 x the ULN if liver metastasis performed within 30 days prior to the date of registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN, aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); if a patient has liver metastases, ALT and AST < 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 2 x institutional ULN within 14 days of enrollment to trialXx_NEWLINE_xXalanine aminotransferase /aspartate aminotransferase (ALT/AST) ?2.5 x ULN without, and ? 5 x ULN with hepatic metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3.0 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases within 8 weeks of pre-registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (ALT) and alanine aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN or =< 5 x ULN if liver mets are presentXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN OR ?5 × institutional ULN for participants with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) at =< 2.5 x ULN (in case of liver metastasis AST/ALT at =< 5.0 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ?5 times ULN).Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (AST) and aspartate aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXPHASE I: Transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x ULN for patients without tumor involvement of the liver or >5 x ULN for patients with tumor involvement of the liver.Xx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase ? 3 x ULN.Xx_NEWLINE_xXPatients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 3 x ULN; (up to 5 x ULN if liver metastases present)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for patients with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 times the ULN; if liver metastases are present, then ? 5 times the ULN is allowed.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) up to 2.5 x upper limits of normal (ULN).\r\n* Patients known to have Gilbert’s disease may be eligible with AST and ALT up to 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN within four weeks of enrollmentXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXObtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X ULN (or < 5 x ULN with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3.0 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULNXx_NEWLINE_xXSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 x the ULN for the reference lab (=< 5 x the ULN if there is evidence of hepatic involvement by malignant disease)Xx_NEWLINE_xXSerum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine-aminotransferase (ALT) levels =< 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN, (=< 5.0 x ULN with documented liver metastases) within 14 days prior to first dose of protocol-indicated treatment.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception: patients with liver involvement: AST and/or ALT =< 5 x ULN.Xx_NEWLINE_xXWithin 14 days of the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.Xx_NEWLINE_xXAlanine aminotransferase (ALT) level =< 2.5 × ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) < 3 x ULN, unless due to the underlying leukemia approved by the PIXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3x the ULN (?5x the ULN for subjects with liver metastases)Xx_NEWLINE_xXObtained ? 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x institutional ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN, unless liver metastases are present, then values must be ? 5 x ULN)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN unless deemed to be related to underlying leukemia.Xx_NEWLINE_xXAlanine aminotransferase (ALT) ? 3.0 x ULN (unless considered due to leukemic organ involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) > 45 U/LXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine transaminase (ALT) less than 2.5 X institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN (within 14 days of PET imaging)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) level =< 2.5 x ULNXx_NEWLINE_xXObtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless due to liver involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times the ULN range of each institution. With the following exceptions: subjects with documented liver metastases; AST and ALT < 5 x ULN.Xx_NEWLINE_xXAn aspartate aminotransferase (AST) level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN.Xx_NEWLINE_xXSTRATUM B: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility the ULN of ALT and AST is 45 U/LXx_NEWLINE_xXSTRATUM C: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility, the ULN of ALT and AST is 45 U/LXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ? 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULNXx_NEWLINE_xXAST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN (measured within 28 days of registration)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x institutional ULN (? 5 x ULN in the presence of liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN (or ? 5.0 x ULN if hepatic metastases are present)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 4 x ULN for subjects with liver metastasesXx_NEWLINE_xXSTUDY TREATMENT: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 × ULN.Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULNXx_NEWLINE_xXObtained within 14 days prior to randomization/registration:  aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x IULNXx_NEWLINE_xXAlanine aminotransferase (ALT) ? 1.5 x ULNXx_NEWLINE_xXalanine aminotransferase (ALT) <= 3.0 x ULN*Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3x the institutional ULN, except for people with liver involvement by their lymphoma, who may be included if AST/ALT ? 5x the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXObtained within 28 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN orXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN without liver metastasis; =< 5 x ULN with liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)Xx_NEWLINE_xXWithin 3 days before the first dose of study drug: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) if no hepatic metastasis =< 2.5 times x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 3.0 x ULN for the institution within 14 days of study registrationXx_NEWLINE_xXAlanine aminotransferase (alanine aminotransaminase [ALT]) and aspartate aminotransferase (aspartate aminotransaminase [AST]) ? 2.5 x IULNXx_NEWLINE_xXAspartate and Alanine Aminotransferase (AST and ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 7 days prior to first study treatmentXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase and alanine aminotransferase concentrations of =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN (obtained within three days prior to study treatment)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN.Xx_NEWLINE_xXAspartate transaminase (AST) and alanine aminotransferase (ALT) =< 5.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXWithin 28 days prior to enrollment: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN within 14 days of study registration.Xx_NEWLINE_xXAlanine aminotransferase (ALT) (SPGT) is ? 3 X ULN for ageXx_NEWLINE_xXObtained within 21 days prior to randomization/registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN.Xx_NEWLINE_xXWithin 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN except for subjects with liver mets for whom ALT and AST should be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3x ULN unless considered due to leukemic involvementXx_NEWLINE_xXWithin 7 days before the first dose of study treatment: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (results within 7 days before study drug administration), =< 5 x ULN for patients with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN (or > 5 x ULN for patients with concurrent liver metastasis)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or < 5 x ULN if liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the exception that patients with liver involvement: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN or, in the case of liver involvement by the primary disease AST/ALT =< 5 x ULNXx_NEWLINE_xXPerformed within 14 days of treatment initiation: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN within 14 days prior to Step 2 registrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN unless believed due to leukemic infiltrationXx_NEWLINE_xXWithin 14 days of the first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2.5 × ULNXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 times ULN at the time of screeningXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXalanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ? 2.5 x ULN (? 5 x ULN if liver metastases are present);Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULNXx_NEWLINE_xXPatients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN, within 30 days before study registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN and total bilirubin < 2.0 mg/dL unless due to malignancy or Gilbert’s syndrome in the opinion of the PI or designeeXx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase =< 2.5 X ULN except in patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation that is declared to be caused due to liver metastasis, they are allowed to be enrolled as long as < 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXALT (alanine aminotransferase) =< 2 x ULNXx_NEWLINE_xXAspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (=< 5 x institutional ULN if there is liver metastasis)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjectsXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXObtained within 14 days of randomization: Alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXalanine aminotransferase (ALT) ? 3.0 × ULN*Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN (> 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST), level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN prior to biopsyXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXalanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastasesXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 x the upper limit of normal (ULN); if the patient has liver metastases, ALT and AST should be < 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, obtained =< 14 days prior to registrationXx_NEWLINE_xXWithin 14 days prior to planned start of treatment: Alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltrationXx_NEWLINE_xXAspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) ?3.0 x ULNXx_NEWLINE_xXSerum aspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) less than or equal to 3 x ULN (unless due to B-ALL)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN if no demonstrable liver metastases or =< 5 x ULN in the presence of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN should be obtained within 21 days prior to enrollmentXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times ULN or =< 5 times ULN if patient has documented liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastasesXx_NEWLINE_xXAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAlanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULNXx_NEWLINE_xXIn absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver metastases, ALT and AST should be < 5 × ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x ULN, aspartate aminotransferase (AST) =< 1.5 x ULN); ALT and AST =< 5 x ULN if documented liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT):\r\n* > 2.5 x ULN\r\n* > 5 x ULN, if liver metastasis presentXx_NEWLINE_xXAlanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN (=< 5.0 x ULN if due to leukemic involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN unless thought to be disease relatedXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 x ULN for ageXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2 x ULN for the laboratoryXx_NEWLINE_xXPatients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects hepatic metastases, ALT and AST =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5 x ULN, within 14 day prior to registrationXx_NEWLINE_xXAlanine transaminase (alanine aminotransferase [ALT]) > 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN; if liver metastases are present, then AST and ALT =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvementXx_NEWLINE_xXTransaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN and total bilirubin =< 2 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate transaminase (aspartate aminotransferase [AST]) or alanine transaminase (alanine aminotransferase [ALT]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase and/or alanine aminotransferase =< 3 x ULN (=< 5 x ULN if liver metastases are present) within 30 days prior to C1D1Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 4.0 x ULN if hepatic metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X IULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatmentXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN obtained within 14 days prior to randomization/registrationXx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); if the patient has liver metastases, ALT and AST < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN; for patients with liver metastases: AST/ALT > 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXPHASE I: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN if patients have liver involvement with MM)Xx_NEWLINE_xXWithin 3 months of registration: Alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times ULNXx_NEWLINE_xXAspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 times the ULNXx_NEWLINE_xXWithin 14 days prior to study entry: Alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 10 x ULN, unless related to ALL liver infiltrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN for the laboratoryXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (or =< 5.0 x ULN if hepatic metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXalkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)Xx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the ULN unless considered due to organ leukemic involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x ULN, except patients who are assigned to receive docetaxel must have liver function tests (serum transaminases, bilirubin) that are within 1.5 x the ULNXx_NEWLINE_xXMust be met within 28 days of C1D1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x UNL (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXEXCLUSION CRITERIA FOR ENROLLMENT: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULNXx_NEWLINE_xXEXCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULNXx_NEWLINE_xXSerum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be less than or equal to (<=) 2.5*the ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times above the ULN, ALT and AST can be < 5 times ULN if patients have hepatic involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x the ULN prior to biopsyXx_NEWLINE_xXWithin 4 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, obtained within 30 days of study registrationXx_NEWLINE_xXaspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN ^1Xx_NEWLINE_xXWithin 21 days prior to C1D1: Aspartate aminotransferase (AST) < 2.5 times ULN and alanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal rangeXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present (to be performed within 7 days prior to start of study treatment)Xx_NEWLINE_xXAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 X ULN, or for subjects with liver involvement AST and/or ALT > 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4x ULN, unless secondary to diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 189 IU/LXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal or less than 200 IU/ml for adultsXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; andXx_NEWLINE_xXAspartate aminotransferase and alanine aminotransferase < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXWithin 14 days of enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN, unless there are liver metastases in which case AST and ALT or > 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 4 x normalXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXHepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN for patients without liver metastasis, =< 5 x ULN for liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN unless considered due to leukemic involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2 times the ULN or aspartate aminotransferase (AST) =< 2 times the ULN; these values must be obtained within four weeks before protocol entryXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 x ULN if due to lymphoma involvement, without use of growth factor support for 1 weekXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × ULN or < 5 × ULN in the setting of liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) > 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 4x normalXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normalXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x normalXx_NEWLINE_xXAspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 1.5 × ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN without liver metastases (or ? 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver metastases)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) > 2.5 X ULN or cirrhosisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXSerum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ? 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (repeat if more than 3 days before the first dose)Xx_NEWLINE_xXAlanine aminotransferase (ALT) within the reference range during screening evaluationXx_NEWLINE_xXAlanine aminotransferase (ALT) > 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x ULN Inclusion Criteria unique to the ER+ve cohort:Xx_NEWLINE_xXSerum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institutionXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; NOTE: concomitant elevations in ALT/AST above 1.0 x ULN is not permittedXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional ULN or =< 5 x the institution ULN in the presence of known liver metastasesXx_NEWLINE_xXHepatic: bilirubin <1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5x ULNXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULNXx_NEWLINE_xXAspartate aminotransferase and alanine aminotransferase ?2.5 × ULNXx_NEWLINE_xXWithin 14 days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be =< 5 x ULNXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN.Xx_NEWLINE_xXObtained ? 14 days prior to registration: aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 3 x ULNXx_NEWLINE_xXAlanine aminotransferase/aspartate aminotransferase (ALT/AST) =< 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN if patient has liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULNXx_NEWLINE_xXWithin 14 days prior to first dose of study drug treatment: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver metastases: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXBLADDER: Clinical laboratory values at screening: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULNXx_NEWLINE_xXWithin 7 days before the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransfearse (AST) =< 2.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x upper limits of normal (ULN) if liver metastases are present =< 14 days prior to registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 28 days of day 0.Xx_NEWLINE_xXWithin 10 days of treatment initiation: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXWithin 14 days of study registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULNXx_NEWLINE_xXWithin 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase, alanine aminotransferase (AST, ALT) =< 3.0 x ULNXx_NEWLINE_xXLiver function tests performed within 3 weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than or equal to 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase < 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if there is evidence of hepatic involvement by malignant disease)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferease (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with liver metastases may enroll with AST and ALT =< 5 x ULNXx_NEWLINE_xXTransaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) < 6 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN, obtained =< 7 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1Xx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels >= 2.5 times the ULN or >= 5 times the ULN if liver metastases are presentXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) each < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registrationXx_NEWLINE_xXARM A: obtained =< 14 days prior to registration: \r\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXObtained within 30 days prior to registration: Alanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) > 50 U/L or aspartate aminotransferase (AST) > 65 U/LXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the ULN if no liver involvement, or =< 5 x the ULN with liver involvementXx_NEWLINE_xXAlanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXIn absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST =< 5.0 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN in subjects without liver metastases or =< 5.0 times ULN in subjects with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) < 1.5 X ULN; patients with Gilbert's disease are exempt from this criteriaXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, the AST/ALT =< 5 times ULN is acceptableXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x UNL unless related to primary diseaseXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for the institutionXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to metastatic breast cancer to the liver (in which case AST/ALT < 5 x ULN is allowed)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN within 14 days of enrollmentXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN, within 2 weeks of the first dose of study treatmentXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with documented liver metastases)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXTransaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) > 20 x ULN based on age- and laboratory specific normal rangesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x ULN (with or without liver metastasis [mets])Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x institutional ULN; note: patients who have both bilirubin > ULN and AST/ALT > ULN are not eligible (unless they have Gilbert's syndrome and elevations of indirect bilirubin)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN (unless elevated due to secondary lymphomatous involvement of the liver)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasisXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXObtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x IULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN; in the setting of metastatic disease to the liver, AST/ALT may be =< 5 x ULNXx_NEWLINE_xXTotal bilirubin ?1.5 × the upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN.Xx_NEWLINE_xXAspartate and alanine aminotransferase (AST & ALT) ?3.0 x ULN or ?5.0 x ULN if subject has liver metastasis;Xx_NEWLINE_xXPatients must have aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x IULN, unless due to lymphoma, within 42 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN (or 5.0 x ULN in the setting of liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (if both tests are done, both results need to be =< 2.5 x ULN)Xx_NEWLINE_xXCLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases); these results must be obtained within 28 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (institutional)Xx_NEWLINE_xXTotal bilirubin =< 1.5 x IULN or =< 3.0 x IULN with normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in patients with Gilbert’s diseaseXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 x IULNXx_NEWLINE_xXTotal bilirubin > 1.5 x ULN; and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULNXx_NEWLINE_xXWithin 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN; patients with liver metastases may have AST and ALT of =< 5.0 x IULNXx_NEWLINE_xXAMKL PATIENTS: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 times the ULN if no liver metastases; for patients with known liver metastases, AST and ALT must be =< to 5 times the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 X IULN in the absence of liver metastases or =< 5.0 x IULN with liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases and =< 5 x ULN for patients with liver metastasesXx_NEWLINE_xXAsparate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 2 x ULN for the lab. (Note: If AST and/or ALT greater than ULN, serologic testing for Hepatitis B and C must be performed and results must be negative.)Xx_NEWLINE_xXaspartate aminotransferase, alanine aminotransferase ? 2.5 X ULN, or ? 5.0 X ULN (if liver metastasis present)Xx_NEWLINE_xXAlanine aminotransferase (ALT) ? 2 x ULNXx_NEWLINE_xXHepatic: Total bilirubin ? 1.5 x the upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ? 3.0 x ULN OR ? 5.0 x ULN for patients with liver metastases.Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN within 14 days prior to study registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULN OR ALT and AST =< 5.0 x IULN for patients with documented hepatic involvement with NHLXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR or alkaline phosphatase (ALP) > 2.5 x ULRRXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN or alanine aminotransferase (ALT) =< 2.5 x ULN (Note, if both AST and ALT are done, both must be =< 2.5 x ULN) ORXx_NEWLINE_xXAspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) superior to 3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasisXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5*ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate amino-transferase (AST) ? 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)Xx_NEWLINE_xXAlanine aminotransferase less than or equal to 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN, or =< 5.0 x ULN for patients with documented hepatic involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) < or equal to 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN in the presence of liver metastases)Xx_NEWLINE_xXAdequate hepatic function defined as: total bilirubin ?2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 times the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 if due to lymphoma involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present (within 14 days prior to day 1 of protocol therapy)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN)Xx_NEWLINE_xXPrior to cyclophosphamide and T cell infusions: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN (since all patients will have liver metastasis)Xx_NEWLINE_xXIn the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN). If the patient has liver metastases, ALT and AST < 5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases =< 7 days prior to randomizationXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 2.5 x ULN if no liver metastases or ALT or AST up to 5 x ULN if liver metastases presentXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) in the case of liver metastases or AST/ALT =< 1.5 x ULN in patients without liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN (or =< 3 x ULN if liver involved with diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (values post biliary stenting allowed for eligibility)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULNXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine transaminase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXObtained within 14 weeks prior to registration on study: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 4.0 x ULN obtained within 14 days prior to registrationXx_NEWLINE_xXTotal bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/LXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 × ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 times the ULN, unless subjects have liver metastasis, in which case both AST and ALT must be less than or equal to 5 times the ULNXx_NEWLINE_xXAlanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 2.5 x ULN (for patients with liver metastases, =< 5 x ULN)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) obtained =<14 days prior to randomizationXx_NEWLINE_xXalanine aminotransferase (ALT) less than or equal to 2.5 × ULN*Xx_NEWLINE_xXObtained =< 21 days prior to registration: Alanine aminotransferase (ALT) =< 3 x institutional ULNXx_NEWLINE_xXAST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 x ULN if no liver involvement or =< 4 x the ULN if known liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastasesXx_NEWLINE_xXAspartate transaminase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase; and, Aspartate aminotransferase AST and ALT<=2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 * ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 × IULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULNXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ?2.5 × ULN. For subjects with bone metastases and/or suspected disease-related liver or biliary involvement, ALP must be ?5 × ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) > 3.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 2.5 x ULNXx_NEWLINE_xXCOHORT A: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXSerum alanine aminotransferase or aspartate aminotransferase > 3 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN unless associated with hepatic metastases, then ALT and AST ? 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN, alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) ? 5 × institutional ULNXx_NEWLINE_xXWithin 30 days prior to initiation of protocol treatment: Alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAdequate hepatic function, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1); aspartate aminotransferase measurement (AST) and alanine aminotransferase measurement (ALT) ? 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ? 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)Xx_NEWLINE_xXAlanine aminotransferase and/or aspartate transaminase =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 times ULN*Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN if caused by liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< grade 3Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULNXx_NEWLINE_xXPatients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULNXx_NEWLINE_xXNo liver metastases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; liver metastases: AST and ALT =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, or =< 5 x institutional ULN in subjects with liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXObtained =< 7 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase must be within the range allowing for eligibilityXx_NEWLINE_xXAlanine aminotransferase (ALT) < 5 x ULN ageXx_NEWLINE_xXSerum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note: If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor to discuss.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN (for patients with known liver metastasis, AST or ALT =< 3 x ULN is allowed) at the screening visitXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine transaminase (ALT) and aspartate aminotransferase (AST) ? 2.5 × ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN (or < 5 x ULN if known liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN (AST and ALT > 5 x ULN for subjects with liver metastasis)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN in the absence of liver metastases; AST and ALT =< 5 x ULN in the presence of liver metastasesXx_NEWLINE_xXHepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for the institutionXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN if no liver involvement, or =< 5 X ULN with liver involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for institution or =< 5 x ULN for institution if clearly attributable to liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in AST/ALT above 1.0 X ULN are not permittedXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT): ~ 2.5 x ULN for subjects without liver metastasis ~ 5 times for liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normalXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULNXx_NEWLINE_xXFor subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST)  =< 2.5 x ULN or =< 5.0 x ULN for subjects with liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (or =< 3 x ULN if liver involved with diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULNXx_NEWLINE_xXAspartate aminotransferase or alanine aminotransferase > 1.5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULNXx_NEWLINE_xXWithin 8 weeks of randomization: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase < 2.5 of the ULN (< 5 x of ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x normalXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXHepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 ULN in the presence of liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase > 100 IU/LXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) ?3 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate and alanine aminotransferase (AST and ALT) =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless liver metastases, who can have AST/ALT =< 5 x ULN)Xx_NEWLINE_xXAlanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ?3 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 times ULN for participants without liver metastases, or ?5 times ULN in the presence of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times ULN for subjects without liver metastases, or ? 5 times ULN in the presence of liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN (patients with documented liver metastases: AST and/or ALT =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with hepatic involvement with tumor)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary diseaseXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x ULN for subjects without liver metastasis; =< 5 times for liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULNXx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase </= 3 times the ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 300 IU/mlXx_NEWLINE_xXAlanine aminotransferase (AST) or aspartate aminotransferase (ALT) > 3.0 x ULN (or < 5.0 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ? 5 x ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXPatients must have adequate hepatic function with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN within one week prior to treatmentXx_NEWLINE_xXElevated serum aspartate aminotransferase, alanine aminotransferase, or bilirubin (unless there is medical justification for bilirubin elevation, and aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase are normal)Xx_NEWLINE_xXAspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN for patients with documented liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN, or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancyXx_NEWLINE_xXSerum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? 2.5 x ULN in the absence of liver metastases or =< 5 ULN in case of liver metastases)Xx_NEWLINE_xXSerum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) < 2.5 x ULN; for patients with liver metastases, ALT/AST < 5 x ULN is acceptableXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (for subjects with liver metastases AST/ALT may be =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alkaline phosphatase =< 2.5 x ULN (CTCAE v4.03 grade 1; AST and alanine aminotransferase [ALT] =< 3 x ULN [or =< 5.0 x ULN if hepatic metastases are present])Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x ULN, +/- 7 days from date of ICF signingXx_NEWLINE_xXSerum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) must be =< 1.5 x ULN for the labXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN unless metastatic to liver in which case AST and ALT should be < 5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, unless due to liver involvement with lymphomaXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x ULNXx_NEWLINE_xXSerum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) levels must be =< 2.5 x ULN, or =< 5 X ULN for patients with liver involvement by lymphomaXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 2.5X the ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless ALT or AST elevation is thought to be related to underlying AML, in which case ALT and AST should be =< 5.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x UNLXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5.0 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN for ageXx_NEWLINE_xXalanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 times the ULN for the reference labXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented liver metastases, the AST/ALT may be =< 5 x ULNXx_NEWLINE_xXAdequate laboratory parameters [absolute neutrophil (ANC), platelets, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine and coagulation parameters] at screeningXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 ×ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN (or < 5 x ULN in subjects with liver metastases or hepatocellular carcinoma).Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2x institutional ULN unless it is related to the primary diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) of =< 2 ULNXx_NEWLINE_xXThe subject has aspartate aminotransferase and/or alanine aminotransferase > 1.5 × ULN, with concomitant alkaline phosphatase > 2.5 × ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) </=2.5 times ULN (</=5 times ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULN and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXSerum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) <=2.5*ULN • For participants to be treated with MLN4924 + docetaxel in Part B, AST and ALT must be <=1.5*ULN, and total bilirubin should be within the normal range.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN or =< 5.0 x ULN in case of documented hepatic metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5xULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (ALT and AST =< 2.5 x ULN is acceptable if there is liver metastasis)Xx_NEWLINE_xXSerum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 ULN if hepatic involvement is present as determined by the investigatorXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN obtained =< 7 days prior to registration (=< 5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN if no liver involvement, or =< 5 x ULN with liver involvementXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 X ULNXx_NEWLINE_xXAspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ?2.5 X ULN (?5 x ULN in patients with liver metastases)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entryXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal rangeXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (with or without liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN or < 5 x ULN if known liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)Xx_NEWLINE_xX< 3 x ULN alanine aminotransferase (ALT), unless there is congenital benign hyperbilirubinemiaXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 14 days prior to initiation of study drugXx_NEWLINE_xXCohort A: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvementXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5× ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 x ULN unless liver metastasis is present then up to 5 X ULN permittedXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) ?3xULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 X ULN in case of liver metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN;Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 5 x ULN for age, unless the elevation is disease-relatedXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times the ULN (>= 5 x ULN for patients with liver involvement)Xx_NEWLINE_xXAlanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP): all three < 2.5 x ULRR, or < 5 x ULRR if judged by the investigator to be related to liver metastasesXx_NEWLINE_xXHad at least one liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) with normal results in the last yearXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/mlXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary diseaseXx_NEWLINE_xXNormal organ function tests including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXSerum alanine aminotransferase < 2.5 times the ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) or alanine transaminase (ALT) > 5 times ULNXx_NEWLINE_xXSerum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note:If elevated liver enzymes are related to disease; contact medical monitor to discuss.Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and ALT < 3.0 × ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastasesXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase or aspartate aminotransferase >= 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x ULN (5 x ULN for those with lymphoma involvement of the liver)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 2.5 x IULN within 28 days prior to registrationXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST, and alanine aminotransferase (ALT) =< 1.5 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasisXx_NEWLINE_xXAlanine aminotransferase (ALT) > 3 x ULN for the laboratoryXx_NEWLINE_xXAlanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXObtained within 14 days prior to initiation of treatment: Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for institutionXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ? 2.5xULNXx_NEWLINE_xXAdequate laboratory parameters [absolute neutrophil (ANC), platelets, asparate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, creatinine and coagulation parameters] at screeningXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, obtained within 14 days of the first dose of study drugXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/LXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXSerum alanine aminotransferase ? (ALT) 2.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x institutional ULNXx_NEWLINE_xXKnown alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR orXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) < 1.5 x ULN, aspartate aminotransferase (AST) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless benign congenital hyperbilirubinemia)Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULNXx_NEWLINE_xXHepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (unless determined by treating physician to be related to underlying malignancy)Xx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXHave significant hepatic dysfunction (aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 2 x ULN or reported liver disease)Xx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.8 X ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRRXx_NEWLINE_xXAspartate aminotransferase (AST), alanine aminotransferase (ALT) within 2 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN, obtained within 14 days prior to PET scanXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary diseaseXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN obtained < 2 weeks prior to study enrollmentXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN (institutional upper limits of normal); > 5 x ULN if liver metastasisXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, completed within 2 weeks prior to start of protocol therapyXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN in the absence of known metastatic involvement of the liver or AST and ALT =< 5.0 x ULN if there is metastatic liver involvementXx_NEWLINE_xXSerum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 1.5 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULNXx_NEWLINE_xXc. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ? 3.0 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5×ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN for the lab utilizedXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjectsXx_NEWLINE_xXAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) within the normal range at the screening visitXx_NEWLINE_xXAspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULNXx_NEWLINE_xXLaboratory values for hemoglobin, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and serum creatinine or calculated/measured creatinine clearance.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be <=2.5*ULN.Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x ULN if no liver involvement or ?5 x ULN with liver involvement.Xx_NEWLINE_xXTotal bilirubin ?1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5*ULN (?5*ULN if liver metastases are present).Xx_NEWLINE_xXAlanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN (? 5 times ULN for patients with impaired liver function due primary tumor or metastatic disease)Xx_NEWLINE_xXaspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 X institutional UNL,Xx_NEWLINE_xX